Format
Sort by
Items per page

Send to

Choose Destination

Search Tip

Sort by Best Match to display results from highest to lowest relevance to your search terms.

Try it Now

Search results

Items: 1 to 20 of 530

1.

SERAPHIN haemodynamic sub-study: the effect of the dual endothelin receptor antagonist macitentan on haemodynamic parameters and NT-proBNP levels and their association with disease progression in patients with pulmonary arterial hypertension.

Galiè N, Jansa P, Pulido T, Channick RN, Delcroix M, Ghofrani HA, Le Brun FO, Mehta S, Perchenet L, Rubin LJ, Sastry BK, Simonneau G, Sitbon O, Souza R, Torbicki A.

Eur Heart J. 2017 Feb 28. doi: 10.1093/eurheartj/ehx025. [Epub ahead of print]

PMID:
28329315
2.

Evaluation of the incidence of rare diseases: difficulties and uncertainties, the example of chronic thromboembolic pulmonary hypertension.

Simonneau G, Hoeper MM.

Eur Respir J. 2017 Feb 23;49(2). pii: 1602522. doi: 10.1183/13993003.02522-2016. No abstract available.

PMID:
28232419
3.

Hypermethylation of BMPR2 Promoter Occurs in the Patients with Heritable Pulmonary Arterial Hypertension and Inhibits BMPR2 Expression.

Liu D, Yan Y, Chen JW, Yuan P, Wang XJ, Jiang R, Wang L, Zhao QH, Wu WH, Simonneau G, Qu JM, Jing ZC.

Am J Respir Crit Care Med. 2017 Feb 7. doi: 10.1164/rccm.201611-2273LE. [Epub ahead of print] No abstract available.

PMID:
28170297
4.

Clinical phenotypes and outcomes of heritable and sporadic pulmonary veno-occlusive disease: a population-based study.

Montani D, Girerd B, Jaïs X, Levy M, Amar D, Savale L, Dorfmüller P, Seferian A, Lau EM, Eyries M, Le Pavec J, Parent F, Bonnet D, Soubrier F, Fadel E, Sitbon O, Simonneau G, Humbert M.

Lancet Respir Med. 2017 Feb;5(2):125-134. doi: 10.1016/S2213-2600(16)30438-6.

PMID:
28087362
5.

Initial combination therapy with ambrisentan and tadalafil in connective tissue disease-associated pulmonary arterial hypertension (CTD-PAH): subgroup analysis from the AMBITION trial.

Coghlan JG, Galiè N, Barberà JA, Frost AE, Ghofrani HA, Hoeper MM, Kuwana M, McLaughlin VV, Peacock AJ, Simonneau G, Vachiéry JL, Blair C, Gillies H, Miller KL, Harris JH, Langley J, Rubin LJ; AMBITION investigators..

Ann Rheum Dis. 2016 Dec 30. pii: annrheumdis-2016-210236. doi: 10.1136/annrheumdis-2016-210236. [Epub ahead of print]

6.

Haemodynamic effects of riociguat in inoperable/recurrent chronic thromboembolic pulmonary hypertension.

Kim NH, D'Armini AM, Grimminger F, Grünig E, Hoeper MM, Jansa P, Mayer E, Neurohr C, Simonneau G, Torbicki A, Wang C, Fritsch A, Davie N, Ghofrani HA.

Heart. 2016 Dec 23. pii: heartjnl-2016-309621. doi: 10.1136/heartjnl-2016-309621. [Epub ahead of print]

7.

Diagnosis and Classification of 17 Diseases from 1404 Subjects via Pattern Analysis of Exhaled Molecules.

Nakhleh MK, Amal H, Jeries R, Broza YY, Aboud M, Gharra A, Ivgi H, Khatib S, Badarneh S, Har-Shai L, Glass-Marmor L, Lejbkowicz I, Miller A, Badarny S, Winer R, Finberg J, Cohen-Kaminsky S, Perros F, Montani D, Girerd B, Garcia G, Simonneau G, Nakhoul F, Baram S, Salim R, Hakim M, Gruber M, Ronen O, Marshak T, Doweck I, Nativ O, Bahouth Z, Shi DY, Zhang W, Hua QL, Pan YY, Tao L, Liu H, Karban A, Koifman E, Rainis T, Skapars R, Sivins A, Ancans G, Liepniece-Karele I, Kikuste I, Lasina I, Tolmanis I, Johnson D, Millstone SZ, Fulton J, Wells JW, Wilf LH, Humbert M, Leja M, Peled N, Haick H.

ACS Nano. 2017 Jan 24;11(1):112-125. doi: 10.1021/acsnano.6b04930.

8.

Long-term outcome in liver transplantation candidates with portopulmonary hypertension.

Savale L, Sattler C, Coilly A, Conti F, Renard S, Francoz C, Bouvaist H, Feray C, Borentain P, Jaïs X, Montani D, Parent F, O'Connell C, Hervé P, Humbert M, Simonneau G, Samuel D, Calmus Y, Duvoux C, Durand F, Duclos-Vallée JC, Sitbon O.

Hepatology. 2016 Dec 20. doi: 10.1002/hep.28990. [Epub ahead of print]

PMID:
27997987
9.

Future perspectives in pulmonary arterial hypertension.

Simonneau G, Hoeper MM, McLaughlin V, Rubin L, Galiè N.

Eur Respir Rev. 2016 Dec;25(142):381-389. doi: 10.1183/16000617.0084-2016. Review.

10.

Rationale and study design of RESPITE: An open-label, phase 3b study of riociguat in patients with pulmonary arterial hypertension who demonstrate an insufficient response to treatment with phosphodiesterase-5 inhibitors.

Hoeper MM, Klinger JR, Benza RL, Simonneau G, Langleben D, Naeije R, Corris PA.

Respir Med. 2017 Jan;122 Suppl 1:S18-S22. doi: 10.1016/j.rmed.2016.11.001.

PMID:
27887774
11.

Long-term outcomes of pulmonary arterial hypertension under specific drug therapy in Eisenmenger syndrome.

Hascoët S, Baruteau AE, Humbert M, Simonneau G, Jais X, Petit J, Laux D, Sitbon O, Lambert V, Capderou A.

J Heart Lung Transplant. 2017 Apr;36(4):386-398. doi: 10.1016/j.healun.2016.10.006.

PMID:
27866929
12.

BMPR2 mutation status influences bronchial vascular changes in pulmonary arterial hypertension.

Ghigna MR, Guignabert C, Montani D, Girerd B, Jaïs X, Savale L, Hervé P, Thomas de Montpréville V, Mercier O, Sitbon O, Soubrier F, Fadel E, Simonneau G, Humbert M, Dorfmüller P.

Eur Respir J. 2016 Dec;48(6):1668-1681. doi: 10.1183/13993003.00464-2016.

PMID:
27811071
13.

Initial combination therapy with ambrisentan and tadalafil and mortality in patients with pulmonary arterial hypertension: a secondary analysis of the results from the randomised, controlled AMBITION study.

Hoeper MM, McLaughlin VV, Barberá JA, Frost AE, Ghofrani HA, Peacock AJ, Simonneau G, Rosenkranz S, Oudiz RJ, White RJ, Miller KL, Langley J, Harris JH, Blair C, Rubin LJ, Vachiery JL.

Lancet Respir Med. 2016 Nov;4(11):894-901. doi: 10.1016/S2213-2600(16)30307-1.

PMID:
27745818
14.

A Clinical and Echocardiographic Score to Identify Pulmonary Hypertension Due to HFpEF.

Berthelot E, Montani D, Algalarrondo V, Dreyfuss C, Rifai R, Benmalek A, Jais X, Bouchachi A, Savale L, Simonneau G, Chemla D, Humbert M, Sitbon O, Assayag P.

J Card Fail. 2017 Jan;23(1):29-35. doi: 10.1016/j.cardfail.2016.10.002.

PMID:
27742455
15.

Macitentan Improves Health-Related Quality of Life for Patients With Pulmonary Arterial Hypertension: Results From the Randomized Controlled SERAPHIN Trial.

Mehta S, Sastry BK, Souza R, Torbicki A, Ghofrani HA, Channick RN, Delcroix M, Pulido T, Simonneau G, Wlodarczyk J, Rubin LJ, Jansa P, Hunsche E, Galiè N, Perchenet L, Sitbon O.

Chest. 2017 Jan;151(1):106-118. doi: 10.1016/j.chest.2016.08.1473.

16.

Future Directions in Chronic Thromboembolic Pulmonary Hypertension. Disease at a Crossroads?

Kim NH, Simonneau G.

Ann Am Thorac Soc. 2016 Jul;13 Suppl 3:S255-8. doi: 10.1513/AnnalsATS.201601-065AS.

PMID:
27571007
17.

Non-invasive diagnosis of pulmonary hypertension from lung Doppler signal: a proof of concept study.

Godinas L, Lador F, Schatzberger R, Günther S, Segel MJ, Palti Y, Maisuls E, Sitbon O, Simonneau G.

J Clin Monit Comput. 2016 Aug 19. [Epub ahead of print]

PMID:
27541954
18.

Dasatinib induces lung vascular toxicity and predisposes to pulmonary hypertension.

Guignabert C, Phan C, Seferian A, Huertas A, Tu L, Thuillet R, Sattler C, Le Hiress M, Tamura Y, Jutant EM, Chaumais MC, Bouchet S, Manéglier B, Molimard M, Rousselot P, Sitbon O, Simonneau G, Montani D, Humbert M.

J Clin Invest. 2016 Sep 1;126(9):3207-18. doi: 10.1172/JCI86249.

19.

Direct-Acting Antiviral Medications for Hepatitis C Virus Infection and Pulmonary Arterial Hypertension.

Savale L, Chaumais MC, Montani D, Jaïs X, Hezode C, Antonini TM, Coilly A, Duclos-Vallée JC, Samuel D, Simonneau G, Humbert M, Sitbon O.

Chest. 2016 Jul;150(1):256-8. doi: 10.1016/j.chest.2016.04.031. No abstract available.

PMID:
27396788
20.

Quality of life in patients with chronic thromboembolic pulmonary hypertension.

Mathai SC, Ghofrani HA, Mayer E, Pepke-Zaba J, Nikkho S, Simonneau G.

Eur Respir J. 2016 Aug;48(2):526-37. doi: 10.1183/13993003.01626-2015. Review.

Supplemental Content

Loading ...
Support Center